



## Arena Pharmaceuticals to Participate in Upcoming Investor Conferences

September 3, 2020

SAN DIEGO, Sept. 3, 2020 /PRNewswire/ -- [Arena Pharmaceuticals, Inc.](#) (Nasdaq: ARNA) today announced that that members of its senior management team will participate in the upcoming investor conferences:

- Wells Fargo Virtual Healthcare Conference – Presenting on Wednesday, September 9, at 1:20 PM ET
- Citi 2020 BioPharma Virtual Conference – Hosting investor meetings on Thursday, September 10
- H.C. Wainwright Virtual Global Investment Conference – Presenting on Monday, September 14, at 10:00 AM ET
- Cantor Virtual Global Healthcare Conference – Presenting on Wednesday, September 16, at 2:00 PM ET

A live audio webcast of the available presentations will be posted under the [investor relations](#) section of Arena's website at [www.arenapharm.com](http://www.arenapharm.com). A replay of the presentations will be available for 30 days following each event.

### About Arena Pharmaceuticals

[ARENA Pharmaceuticals](#) is a team with a singular purpose – deliver our important medicines to patients.

In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get our medicines to patients, and relentlessly execute until it's done.

ARENA - *Care More. Act Differently.*

### Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's participation in upcoming investor conferences and Arena's purpose, work, understanding, ideas, and execution. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

### Corporate Contact:

Megan E. Knight  
Arena Pharmaceuticals, Inc.  
Director, Investor Relations  
[mknight@arenapharm.com](mailto:mknight@arenapharm.com)  
858.210.3635

### Arena Media Contact:

[IR@arenapharm.com](mailto:IR@arenapharm.com)  
858.453.7200



